Tags

Type your tag names separated by a space and hit enter

Interstitial Nephritis

Interstitial Nephritis is a topic covered in the 5-Minute Clinical Consult.

To view the entire topic, please or purchase a subscription.

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:

Medicine Central

-- The first section of this topic is shown below --

Basics

Description

  • Acute and chronic tubulointerstitial diseases result from the interplay of renal cells and inflammatory cells. Lethal or sublethal injury to renal cells leads to new local antigen expression, inflammatory cell infiltration, and proinflammatory activation and cytokines. Cytokines are produced by macrophages, lymphocytes, and renal cells (i.e., proximal tubule, vascular endothelial cells, interstitial cells, fibroblasts). The outcome is acute interstitial nephritis (AIN) or chronic interstitial nephritis (CIN).
  • Central component in AIN is altered tubular function, which precedes decrements in filtration rate.
  • AIN presents as acute kidney injury (AKI) after the use of offending drugs or agents (OFA) and is associated with typical findings of proteinuria, hematuria, and white cell casts. Less frequently, AIN is secondary to infections, systemic diseases, and mixed connective tissue disease (MCTD).
  • System(s) affected: renal/urologic, endocrine/metabolic, immunologic
  • Synonym(s): acute interstitial allergic nephritis

Epidemiology

Pediatric Considerations
  • Children with history of lead poisoning are more likely to develop CIN as young adults.
  • Tubulointerstitial nephritis with uveitis (TINU) presents in adolescent females with mean age of 15 years.

Incidence
  • AIN account for 15–20% of AKI.
  • Peak incidence in women 60 to 70 years of age

Geriatric Considerations
Elderly (≥65 years) have severe disease and increased risk of permanent damage given polypharmacy, specifically drug-induced AIN (87% vs. 64%), proton pump inhibitor–induced AIN (18% vs. 6%), but less AIN from autoimmune or systemic causes (7% vs. 27%) than younger adults (1)[B].

Etiology and Pathophysiology

  • AIN
    • Delayed drug hypersensitivity reactions
    • Causes AKI
    • Renal dysfunction generally is partially or completely reversible, possibly reflecting the regenerative capacity of tubules with a preserved basement membrane.
    • Hypersensitivity to drugs (75%): not dose dependent. The top three drug causes were omeprazole (12%), amoxicillin (8%), and ciprofloxacin (8%) (2)[C].
      • Antibiotics (e.g., penicillins, cephalosporins, sulfonamides, tetracycline, vancomycin, fluoroquinolones, macrolides, TB meds)
      • Proton pump inhibitors
      • Antivirals (indinavir)
      • NSAIDs (all, including Cox-2 inhibitors)
      • Diuretics (thiazide, loop, and triamterene)
      • Miscellaneous (allopurinol, H2 blockers, diphenylhydantoin, and 5-aminosalicylates such as sulfasalazine [Azulfidine] and mesalamine)
    • Infections: Legionella, Leptospira, streptococci, CMV, Mycobacterium tuberculosis (5–10%)
    • Autoimmune disorders (e.g., SLE, Sjögren syndrome, sarcoidosis, Wegener granulomatosis, cryoglobulinemia) (10–15%)
    • Toxins (e.g., snake bite venom)
  • CIN
    • Follows long-term exposure to OFA (e.g., heavy metals, especially lead)
    • Often found on routine labs or evaluation for hypertension (HTN)
    • Characterized by interstitial scarring, fibrosis, and tubular atrophy, resulting in progressive chronic kidney disease (CKD)

General Prevention

  • Early recognition and prompt discontinuation of OFA
  • Avoid further nephrotoxic substances.

Commonly Associated Conditions

CIN

  • Chronic pyelonephritis
  • Abuse of analgesics
  • Lithium use
  • Gout and gout therapy
  • Immune disorders
  • Malignancy (lymphoma, multiple myeloma)
  • Amyloidosis
  • Exposure to heavy metals (e.g., lead, cadmium)
  • Renal papillary necrosis

-- To view the remaining sections of this topic, please or purchase a subscription --

Citation

Stephens, Mark B., et al., editors. "Interstitial Nephritis." 5-Minute Clinical Consult, 27th ed., Wolters Kluwer, 2019. Medicine Central, im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116840/all/Interstitial_Nephritis.
Interstitial Nephritis. In: Stephens MB, Golding J, Baldor RA, et al, eds. 5-Minute Clinical Consult. 27th ed. Wolters Kluwer; 2019. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116840/all/Interstitial_Nephritis. Accessed June 27, 2019.
Interstitial Nephritis. (2019). In Stephens, M. B., Golding, J., Baldor, R. A., & Domino, F. J. (Eds.), 5-Minute Clinical Consult. Available from https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116840/all/Interstitial_Nephritis
Interstitial Nephritis [Internet]. In: Stephens MB, Golding J, Baldor RA, Domino FJ, editors. 5-Minute Clinical Consult. Wolters Kluwer; 2019. [cited 2019 June 27]. Available from: https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116840/all/Interstitial_Nephritis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Interstitial Nephritis ID - 116840 ED - Stephens,Mark B, ED - Golding,Jeremy, ED - Baldor,Robert A, ED - Domino,Frank J, BT - 5-Minute Clinical Consult, Updating UR - https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116840/all/Interstitial_Nephritis PB - Wolters Kluwer ET - 27 DB - Medicine Central DP - Unbound Medicine ER -